57 results about "Myeloma cell" patented technology

The invention provides a monoclonal antibody capable of recognizing a recombinant EGF-CRM197 vaccine and a preparation method thereof, on the basis of researching, developing and preparing the recombinant EGF-CRM197 vaccine, after the recombinant EGF-CRM197 vaccine is further immunized and inoculated to a mouse, mouse spleen cells and mouse myeloma cells are fused, and the monoclonal antibody capable of recognizing the recombinant EGF-CRM197 vaccine is obtained. And screening a hybridoma cell strain which generates a specific monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine, and sequencing to obtain an antibody sequence. After the hybridoma cells are cultured in a mouse body, the monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine can be prepared in vitro through methods of chromatographic purification and the like. The method can be used for detecting the release titer of the recombinant EGF-CRM197 vaccine and evaluating the immune efficacy after the recombinant EGF-CRM197 vaccine is immunized.

The invention discloses a monoclonal antibody targeting all CD45 subtypes and application of the monoclonal antibody, and belongs to the field of monoclonal antibody preparation. The hybridoma cell strain capable of stably secreting all anti-human CD45 subtype antibodies is successfully obtained by stably expressing short and long molecular subtypes of human CD45 extracellular regions in L929 mouse fibroblasts, immunizing BALB / c mice with L929 cells expressing the two molecular subtypes of human CD45, and fusing splenocytes with SP20 myeloma cells after the serum titer reaches the standard. And the monoclonal antibody targeting all subtypes of CD45 is obtained. The monoclonal antibody provided by the invention shows a high-affinity binding characteristic with all human CD45 molecular subtypes, has important application value in the aspect of human CD45 molecular detection, and can be used as a therapeutic antibody in the fields of tumor immunotherapy, autoimmune disease treatment, transplant rejection resistance and the like.

The invention belongs to the technical field of biology, provides an anti-IL-8 monoclonal antibody, a variable region sequence of the anti-IL-8 monoclonal antibody and application of the anti-IL-8 monoclonal antibody, and discloses a monoclonal antibody with neutralizing interleukin-8 (IL-8) biological activity and the variable region sequence of the monoclonal antibody. The preparation method comprises the following steps: by taking IL-8 as an immune source and a mouse as an immune object, carrying out immune injection on the mouse, taking the spleen of the immune mouse to prepare a suspension, and carrying out cell fusion on the suspension and myeloma cells to obtain a hybridoma cell strain capable of expressing the anti-IL-8 monoclonal antibody so as to prepare the anti-IL-8 monoclonal antibody; according to the invention, a variable region amino acid sequence of the anti-IL-8 monoclonal antibody is cloned at the same time; the anti-IL-8 monoclonal antibody disclosed by the invention can be specifically combined with IL-8, so that the anti-IL-8 monoclonal antibody can be used for treating diseases related to abnormal or excessive or out-of-control expression and secretion of the IL-8.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

The invention belongs to the technical field of biological medicine, and particularly relates to multiple myeloma targeting nano microspheres and application thereof. The invention provides a delivery system for targeting multiple myeloma, the delivery system has different targeting molecules for bone targeting and cancer cell targeting, and multiple myeloma cells in a bone marrow microenvironment can be targeted. Furthermore, the delivery system is carried on the Selinexor, so that the selective delivery of the Selinexor on myeloma cells and affected bone tissues can be enhanced. In-vivo studies show that the delivery system significantly improves the treatment effect of MM. Malignant proliferation of myeloma cells is effectively inhibited, the bone density is increased, the bone microstructure is improved, and bone deterioration in an MM mouse model is relieved. The method for delivering the anti-MM drug through the dual-targeting nanoparticles represents an innovative strategy, MM cancer cell targeting and cancer microenvironment bone targeting are combined, and the method is never applied to MM treatment before.

The present application relates to the field of biotechnology and in vitro diagnosis, and relates to a monoclonal antibody of eosinophil peroxidase and application thereof. The antibody of the present application is mainly used for detecting the content of eosinophil peroxidase by western blot. The monoclonal antibody of eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody of eosinophil peroxidase specifically recognizes the linear epitope of eosinophil peroxidase.

The present invention provides a monoclonal antibody that recognizes a recombinant EGF-CRM197 vaccine and a preparation method thereof. Based on the research and development and preparation of a recombinant EGF-CRM197 vaccine, the present invention further immunizes mice with the recombinant EGF-CRM197 vaccine, fuses the mouse spleen cells with mouse myeloma cells, screens and produces a hybridoma cell line of specific monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine, and obtains the antibody sequence after sequencing. After the hybridoma cells are cultured in mice, monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine can be prepared in vitro by methods such as chromatography purification. The present invention can be used for the release potency detection of the recombinant EGF-CRM197 vaccine and for evaluating the immune efficacy after immunization with the recombinant EGF-CRM197 vaccine.

The invention discloses a series of colchicine deuterated derivatives for resisting multiple myeloma, which can effectively inhibit proliferation of multiple myeloma cells by improving the metabolic effect of colchicine in the multiple myeloma cells and overcome the defect of large toxic and side effects of metabolism of original drugs. According to the series of colchicine deuterated derivatives capable of resisting multiple myeloma, colchicine is used as a raw material, two reactions of demethylation and deuterated methyl are sequentially performed to obtain a target compound, the reaction steps are few, the reaction conditions are mild, the operability is high, and the efficiency is high.

The invention discloses a method for inducing cell copper death based on GK921 and application of the GK921, and relates to the technical field of biological medicine. The invention discloses a brand new function of inducing copper death by a known compound GK921 for the first time, and provides a brand new strategy for solving the problems of drug resistance and relapse of multiple myeloma. According to the method, target cells are treated with an effective amount of GK921, expression of copper ion transporter ATP7A in the cells is specifically reduced, copper ions are accumulated, and then typical copper death events such as iron-sulfur cluster protein reduction and DLAT protein oligomerization are caused. Experiments show that the GK921 can efficiently inhibit the activity of multiple myeloma cell lines and primary cells, and the IC50 value and the low toxicity to normal cells show excellent selectivity. On the basis, GK921 can be used for preparing a pharmaceutical composition for inducing copper death, and particularly has an important application prospect in treatment of multiple myeloma.

Provided are human therapeutic compositions including a compound comprising a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compound is a reaction product of an aldehyde and a harmine component. The compositions exhibit anti-cancer properties, particularly against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

The application relates to the technical field of monoclonal antibodies, and specifically discloses an anti-p-Tau181 antibody and a preparation method and application thereof. The preparation method of the anti-p-Tau181 antibody comprises the following steps: taking a p-Tau181 polypeptide IPAKTPPAPK(pT)PPSSGEPPK as an immunogen, injecting the immunogen into experimental animals to perform an immune response, and obtaining spleen lymphocytes of the experimental animals; taking myeloma cells and the spleen lymphocytes to perform mixed culture to obtain fusion cells; culturing the fusion cells, obtaining supernatant, and performing ELISA detection; the polypeptide used for detection is the p-Tau181 polypeptide; taking the hybridoma cell strain with a positive detection result to perform counter screening with a p-Tau217 polypeptide, a p-Tau231 polypeptide and t-tau protein; screening a positive clone which has a reaction to the p-Tau181 polypeptide and has no reaction to the p-Tau217 polypeptide, the p-Tau231 polypeptide and the t-tau protein; performing multiple cloning screening; obtaining a hybridoma cell strain which can secrete antibodies every time; and taking the antibodies secreted by the hybridoma cell strain as the anti-p-Tau181 antibody. The anti-p-Tau181 antibody can be specifically combined with the p-Tau181, and thus can be used for detecting Alzheimer's disease.

The application provides an abnormal prothrombin detection kit and application thereof, and relates to the technical field of in-vitro detection.The application provides a kit for abnormal prothrombin detection, which comprises an abnormal prothrombin antibody, wherein the abnormal prothrombin antibody is derived from a hybridoma cell strain 7E8-4-4-1 of fusion of myeloma cells and mouse B cells, and the hybridoma cell strain 7E8-4-4-1 is preserved in the China General Microbiological Culture Collection Center on October 28, 2025, with a preservation number of CGMCC No.46709.The kit has a large detection range, a small lower limit of detection and high accuracy, and has great application potential in the detection of abnormal prothrombin.

The invention provides an application of an ANXA1 protein or an antagonist thereof in preparation of a medicine for treating multiple myeloma. After the multiple myeloma BCMA immunotherapy, when BCMA negative recurrence occurs, in multiple myeloma cells, a BCMA receptor signal channel is reduced, ANXA1 protein expression quantity is increased, proliferation of the multiple myeloma cells is promoted, and CAR-T cell immunocompetence and immune persistence are inhibited at the same time. The antagonist of the ANXA1 protein reduces the expression quantity of the ANXA1 protein, inhibits the proliferation of multiple myeloma cells, and recovers the immunocompetence and immune persistence of CAR-T cells at the same time. According to the application, the biological function of the ANXA1 in the MM cells is defined, the action mechanism of the ANXA1 antagonist for treating the BCMA negative MM cells and improving the activity of the CAR-T cells is proved, a valuable theoretical basis is provided for improvement of clinical myeloma CAR-T cell treatment, and finally the disease-free lifetime of a patient after BCMA-targeted immunotherapy is prolonged.

The invention discloses an application of a CaMKII-gamma inhibitor serving as a bortezomib-resistant multiple myeloma treatment medicine. On the basis of si-RNA, cell proliferation activity can be inhibited by down-regulating expression of CaMKII-gamma in bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, a small molecule compound rucotinib capable of effectively inhibiting activity of CaMKII-gamma kinase is obtained through high-throughput screening, growth of multiple myeloma U266 cells and KMS11 cells can be obviously inhibited, and the activity of the rucotinib can be effectively inhibited. The compound has an obvious inhibition effect on the growth of bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, also has an obvious inhibition effect on the growth of U266.BR transplantation tumors, and shows a good tumor inhibition effect as a potential medicine for treating multiple myeloma and bortezomib-resistant multiple myeloma.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention provides an anti-trihexylol monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. The method comprises the following steps: immunizing a Balb / c mouse by using trihexylamine, fusing splenocytes of the mouse with myeloma cells, carrying out specific high-throughput screening to obtain hybridoma cells with high specificity, and carrying out culture and re-immunization to obtain a large amount of mouse ascites. And the monoclonal antibody resisting the trihexylamine with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting the trihexylamine. Through verification, the monoclonal antibody for resisting the trihexylamine disclosed by the invention has good specific binding capacity.

The invention provides application of a c-Myc G4 targeting small molecule drug in preparation of a drug for treating multiple myeloma, and belongs to the technical field of multiple myeloma. The pharmaceutical composition for treating multiple myeloma provided by the invention takes a compound shown as a formula Y502-2304 or a pharmaceutically acceptable salt thereof as an active ingredient or a main active ingredient, and is supplemented with a pharmaceutically acceptable carrier. In multiple myeloma, the compound Y502-2304 regulates apoptosis and cycle progress of cells by stabilizing the c-Myc G4 structure, promotes death of myeloma cells, can be used as a drug for treating multiple myeloma, and provides a new thought for research and development of drugs for resisting multiple myeloma. # imgabs0 #

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

A blocking monoclonal antibody screening method based on a porcine PD-1 / PD-L1 monoclonal antibody and a heterologous Fc fusion protein comprises the following steps: (a) preparing a porcine PD-1 or PD-L1 extracellular region recombinant protein; (b) immunizing mice by using the recombinant protein to obtain immune spleen cells; (c) fusing the immune spleen cells with myeloma cells to obtain hybridoma cells; (d) screening and subcloning a hybridoma cell strain capable of secreting an anti-porcine PD-1 or PD-L1 antibody; (e) preparing a porcine PD-L1-rabbit Fc fusion protein; and (f) evaluating the blocking effect of the monoclonal antibody on PD-1 / PD-L1 binding by using the PD-L1-rabbit Fc fusion protein through flow cytometry.

This invention relates to the field of traditional Chinese medicine composition technology, and particularly to an oral traditional Chinese medicine composition for treating multiple myeloma and its preparation method. It comprises the following components in parts by weight: Bupleurum chinense 10-12 parts, Cyperus rotundus 8-10 parts, Curcuma longa 8-10 parts, Oroxylum indicum 5-6 parts, Angelica sinensis 8-10 parts, Paeonia lactiflora 8-10 parts, Atractylodes macrocephala 10-12 parts, Poria cocos 10-12 parts, Codonopsis pilosula 8-10 parts, Glycyrrhiza uralensis (processed) 5-6 parts, Agrimonia pilosa 6-8 parts, Bambusa textilis 8-10 parts, Mentha haplocalyx 4-6 parts, and Zingiber officinale 4-6 parts. The composition provided by this invention not only directly inhibits the growth of myeloma cells, but also comprehensively improves the survival prognosis of model animals by regulating liver and spleen function, improving immune status, and reducing phlegm-heat and blood stasis. It provides a stable, safe, and easily promoted oral traditional Chinese medicine preparation for the clinical treatment of multiple myeloma.

The invention belongs to the technical field of biological detection and antibody preparation, and particularly relates to an antigen detection target of enterocytozoon hepatopenaei, a monoclonal antibody for detecting enterocytozoon hepatopenaei and application of the monoclonal antibody. A reverse screening technical route is adopted, enriched EHP is adopted to directly immunize mice, then myeloma cells are fused with splenocytes of the immunized mice to prepare hybridoma cells, and monoclonal antibodies are screened; and carrying out immunoblotting detection on EHP total protein by using the screened monoclonal antibody, carrying out mass spectrometry on specific protein bands, and screening to obtain an antigen detection target EHP0019 of EHP. The EHP0019 is a dominant antigen of the EHP, the EHP can be rapidly, accurately and specifically detected by utilizing the monoclonal antibody for specifically detecting the EHP0019 without nucleic acid extraction and amplification, the specificity is high, the sensitivity is high, and a foundation is laid for prevention and control of the hepatopancreatic microsporidiosis.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the pharmaceutical composition containing CD4+ CTL as an active ingredient. The CD4+ CTL according to the present invention performs a cytotoxic function of directly attacking and killing myeloma cells, thereby extending the progression-free survival of transplant-ineligible myeloma patients, and thus can contribute to increasing the survival rate of the patients. In addition, by using NKG2D+ CD4+ CTL as a biomarker for predicting the prognosis of myeloma patients, it is possible to analyze the CD4+ CTL status of individual patients and thereby establish customized treatment strategies. In addition, by increasing the cytotoxicity of NKG2D+ CD4+ CTL through a specific cytokine treatment, it is possible to more effectively prevent or treat cancer.

The application discloses a myeloma microscopic cell image cancer cell counting method and belongs to the technical field of medical image processing. In order to solve the problem of realizing automatic and accurate counting of myeloma cells, the application collects myeloma multi-channel microscopic image data for adaptive preprocessing, fuses noise suppression and convolution enhancement, obtains pixel gray value of the preprocessed myeloma multi-channel microscopic image, then carries out rough segmentation of cancer cells based on edge constraint to obtain a rough segmentation mask of the image, then carries out deep feature extraction to obtain the deep feature of the pixel of the preprocessed myeloma multi-channel microscopic image, then calculates the average deep feature of the cells, then combines Bayesian prior correction to calculate the probability of the cancer cells through MLP deep modeling, and finally, the application verifies the cancer cell counting result through correlation coefficient calibration combined with clinical prior constraint to obtain the final myeloma cancer cell counting result. The application provides technical support for standardization and normalization of myeloma diagnosis.

The application provides a kind of sandwich detection testosterone monoclonal antibody and its preparation method and application, comprising: step S1, preparation testosterone-3-(O-carboxymethyl) oxime, and it is activated;After activation, take testosterone antibody P2G1, according to proportion, drop the activated testosterone-3-(O-carboxymethyl) oxime is reacted to prepare immunogen;Step S2, based on the prepared immunogen, immunization animal;Step S3, the spleen cell of immunization animal and myeloma cell are fused into hybridoma cell, and the real hybridoma cell is selected;Step S4, antibody is separated and purified from the screened hybridoma cell.The application provides a kind of preparation method of raw material and reagent for testosterone sandwich method detection, solves the problem that the sensitivity of small molecule compound testosterone competition method reagent is insufficient, detection range is narrow, specificity is poor, provides a new thought and method for the rapid, accurate detection of testosterone.

The invention discloses an interferon regulatory factor 4 (IRF4) inhibitor as shown in a formula (1) and a preparation method thereof, and a target product is prepared by taking dinorhydrin as a raw material through reactions such as TBS protection, 4, 4-dimethylation, TBS protection removal, oxidation, esterification, reduction, iodination, cyano substitution, Wittig, hydrolysis, esterification, amidation, condensation and the like. The invention further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM), and further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM). The compound can selectively inhibit the multiplication capacity of IRF4 high-expression myeloma cells, and has a good application prospect in treatment of IRF4 high-expression tumors such as multiple myeloma and lymphoma.

The present application relates to the field of biotechnology and in vitro diagnosis, in particular to a monoclonal antibody against eosinophil peroxidase and its application. The antibody of the present application can directly and specifically capture the eosinophil peroxidase with enzymatic activity, and is used in biological research and clinical diagnosis of eosinophils. The monoclonal antibody against eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody against eosinophil peroxidase specifically recognizes the epitope of eosinophil peroxidase.

The invention belongs to but is not limited to the technical field of biological medicines, and discloses application of a ferroptosis inducer in preparation of a medicine for treating t (4; 14) application in a positive multiple myeloma medicine; the combination of the CD38 monoclonal antibody and the RSL3 is at t (4; 14) a synergistic effect in positive multiple myeloma cells; the action target of the combination of the CD38 monoclonal antibody and the RSL3 medicine is GPX4. The CD38 monoclonal antibody is combined with RSL3 to induce t (4; and 14) positive multiple myeloma cell apoptosis. The CD38 monoclonal antibody is combined with RSL3 to induce t (4; and 14) positive multiple myeloma cell ferroptosis.

The invention provides a monoclonal antibody for sandwich detection of testosterone as well as a preparation method and application thereof, and the preparation method comprises the following steps: step S1, preparing testosterone-3-(O-carboxymethyl) oxime, and activating the testosterone-3-(O-carboxymethyl) oxime; taking a testosterone antibody P2G1 after activation, and dropwise adding the activated testosterone-3-(O-carboxymethyl) oxime according to the proportion for reaction to prepare an immunogen; s2, immunizing an animal based on the prepared immunogen; s3, fusing splenocytes and myeloma cells of the immune animals into hybridoma cells, and selecting real hybridoma cells; and S4, separating and purifying the antibody from the screened hybridoma cells. The invention provides a preparation method of a raw material and a reagent for testosterone sandwich method detection, solves the problems of insufficient sensitivity, narrow detection range and poor specificity of a micromolecule compound testosterone competition method reagent, and provides a new thought and method for rapid and accurate testosterone detection.